Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 9/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6984704 | 0.91 | NR3C1 (0.49) | NR3C1ALDH1A1POLBMEN1HPGD | |
| SCHEMBL6985778 | 0.90 | NR3C1 (0.43) | NR3C1ALDH1A1POLBF2MEN1 | |
| SCHEMBL6976360 | 0.90 | NR3C1 (0.41) | NR3C1ALDH1A1POLBMEN1HPGD | |
| SCHEMBL6978671 | 0.89 | F2 (0.46) | NR3C1ALDH1A1POLBF2 | |
| SCHEMBL6978012 | 0.89 | NR3C1 (0.49) | NR3C1ALDH1A1POLBF2MEN1 | |
| Hydrochloric Acid SCHEMBL6982241 | 0.88 | NR3C1 (0.48) | NR3C1ALDH1A1POLBF2MEN1 | |
| SCHEMBL7958817 | 0.87 | NR3C1 (0.47) | NR3C1ALDH1A1POLBF2MEN1 | |
| SCHEMBL6981742 | 0.85 | NR3C1 (0.49) | NR3C1ALDH1A1POLBF2MEN1 | |
| Hydrochloric Acid SCHEMBL6981773 | 0.85 | ITGB3 (0.41) | NR3C1ALDH1A1F2HTT | |
| SCHEMBL6976662 | 0.85 | F2 (0.60) | NR3C1ALDH1A1POLBF2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0991624-B1 | PHENYLALKYL DERIVATIVES WITH THROMBIN-INHIBITING EFFECT | BOEHRINGER INGELHEIM PHARMA (DE) | 2003-11-19 | — | — | EP | claimed |
| US-6300342-B1 | FOR THERAPY OR INHIBITING THROMBUS FORMATION; FOR THERAPY OF FIBRIN-DEPENDENT INFLAMMATORY CONDITION | BOEHRINGER INGELHEIM PHARM KG (DE) | 2001-10-09 | — | — | US | claimed |
| US-6300342-B1 | FOR THERAPY OR INHIBITING THROMBUS FORMATION; FOR THERAPY OF FIBRIN-DEPENDENT INFLAMMATORY CONDITION | BOEHRINGER INGELHEIM PHARM KG (DE) | 2001-10-09 | — | — | US | disclosed |